All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyDavid R. Nelson, Norman Gitlin, Bradley Freilich et al.|Hepatology|2015Cited by 689
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory ScienceYasser Fouad, Puneet S. Arora, Melissa Palmer et al.|Figshare|2022Cited by 14
Tu1515: CLIMB: A PROSPECTIVE, BLINDED, MULTICENTER U.S. BASED STUDY EVALUATING A MULTI-ANALYTE BLOOD-BASED TEST FOR DETECTING HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH LIVER CIRRHOSISDavid J. Taggart, Mindie H. Nguyen, Shivani Mahajan et al.|Gastroenterology|2025Cited by 1